{
    "symbol": "AMRN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 16:35:23",
    "content": " With these initial savings and future potential efficiencies, it is our objective to maintain our positive contribution margin, defined as U.S. gross profit less U.S. sales and marketing-related expenses, in the U.S. this year, while we focus on gaining pricing and reimbursement to set the right foundation for sales in Europe and for expanding our international business over time, noting that our global growth strategy in its initial stages. In the prior MI data just published in JACC, prespecified and post hoc exploratory analysis showed that, for the primary composite endpoint of 5-point MACE, time to first event was significantly reduced with VASCEPA versus placebo by 26%, equating to an absolute risk reduction of 5.9%, and total events were significantly reduced by 35% in the subgroup of patients with prior MI who are at high risk of another major event. So, that\u2019s really where we stand. So, that\u2019s really where we stand."
}